Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cisplatin 3205Cyclophosphamide 3200Carboplatin 2979Radiotherapy 2790Paclitaxel 2720Gemcitabine 2573pembrolizumab 2388Bevacizumab 2210Docetaxel 2200Fluorouracil 1851Capecitabine 1834Oxaliplatin 1742Dexamethasone 1606Nivolumab 1581Doxorubicin 1503Rituximab 1489Magnetic Resonance Spectroscopy 1391Etoposide 1346Irinotecan 1248Leucovorin 1227Drug Therapy 1205Cytarabine 1131Pemetrexed 1078fludarabine 1065Specimen Handling 1021Vincristine 966Trastuzumab 946Cetuximab 945Prednisone 943Lenalidomide 938

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
small molecule inhibitor THX-B × Clear all
NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡